In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme completes acquisition of AnorMed

Executive Summary

Genzyme has agreed to acquire all outstanding AnorMed common shares for $584mm in cash, or $13.50 per share (about market average). In August, Genzyme offered to pay $380mm ($8.55 a share a 54% premium to market) for the company.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Intra-Biotech Deal
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register